Pfizer-BioNTech COVID-19 An Amince da Alurar rigakafin ga Yara 5-11 don Gaggawa

Mabuɗin mahimmanci ga iyaye da masu kulawa:

• Inganci: Amsoshin rigakafi na yara masu shekaru 5 zuwa 11 sun yi daidai da na mutane masu shekaru 16 zuwa 25. A cikin waccan binciken, maganin ya yi tasiri kashi 90.7% wajen hana COVID-19 a cikin yara 5 zuwa 11.  

• Tsaro: An yi nazarin lafiyar rigakafin a kusan yara 3,100 masu shekaru 5 zuwa 11 waɗanda suka karɓi maganin kuma ba a sami wani mummunan illa ba a cikin binciken da ake yi.  

• Kwamitin Shawarwari na Cibiyoyin Kula da Cututtuka da Cututtuka (CDC) kan Ayyukan rigakafi zai hadu mako mai zuwa don tattauna ƙarin shawarwarin asibiti.

“A matsayina na uwa kuma likita, na san cewa iyaye, masu kulawa, ma’aikatan makaranta, da yara sun jira izinin yau. Alurar riga kafi ga yara kanana daga COVID-19 zai kawo mu kusa da komawa ga yanayin al'ada, "in ji mukaddashin kwamishiniyar FDA Janet Woodcock, MD "cikakkiyar kimantawarmu da tsattsauran bayanan da suka shafi aminci da ingancin rigakafin ya kamata su tabbatar da iyaye da masu kula da su. cewa wannan rigakafin ya dace da manyan ka'idodinmu."

Ana yin allurar Pfizer-BioNTech COVID-19 na yara masu shekaru 5 zuwa 11 a matsayin jerin farko na kashi biyu, tsakanin makonni 3, amma ƙaramin kashi ne (microgram 10) fiye da wanda ake amfani da shi ga mutane masu shekaru 12 da haihuwa. (30 micrograms).

A cikin Amurka, shari'o'in COVID-19 a cikin yara masu shekaru 5 zuwa 11 sune kashi 39% na lokuta a cikin mutane masu ƙasa da shekaru 18. A cewar CDC, kusan shari'o'in COVID-8,300 na COVID-19 a cikin yara masu shekaru 5 zuwa 11 sun haifar da asibiti. Tun daga ranar 17 ga Oktoba, an ba da rahoton mutuwar mutane 691 daga COVID-19 a cikin Amurka a cikin mutanen da ba su wuce shekaru 18 ba, tare da mutuwar 146 a cikin rukunin masu shekaru 5 zuwa 11. 

"FDA ta himmatu wajen yanke shawarar da kimiyya ke jagoranta wanda jama'a da al'ummar kiwon lafiya za su iya amincewa da su. Muna da kwarin gwiwa a cikin aminci, inganci da bayanan masana'antu a bayan wannan izini. A wani bangare na kudurinmu na tabbatar da gaskiya game da yanke shawara, wanda ya hada da taron kwamitinmu na ba da shawara ga jama'a a farkon wannan makon, mun buga takardu a yau da ke goyan bayan shawarar da muka yanke kuma za a buga karin bayani da ke dalla-dalla game da kimanta bayananmu nan ba da jimawa ba. Muna fatan wannan bayanin ya taimaka wajen ƙarfafa amincewar iyaye waɗanda ke yanke shawarar ko za a yi wa ’ya’yansu rigakafin,” in ji Peter Marks, MD, Ph.D., darektan Cibiyar Nazarin Halittar Halitta ta FDA.

FDA ta ƙayyade wannan maganin Pfizer ya cika ka'idojin izinin amfani da gaggawa. Dangane da jimillar shaidar kimiyya da ake da su, sanannun kuma yuwuwar fa'idodin rigakafin Pfizer-BioNTech COVID-19 a cikin mutane masu ƙasa da shekaru 5 sun fi sananne da haɗarin haɗari.